The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).
HSV and varicella zoster virus (VZV) are common pathogens of skin and mucous membranes and the CNS. Their rapid and accurate diagnosis is essential for their treatment as well as infection control.